Induction of quinone reductase by tamoxifen or DPN protects against mammary tumorigenesis

FASEB Journal

Volumn 26, Issue 10, 2012, Pages 3993-4002

  Krishnamurthy, Nirmala ^a   Hu, Yanduan ^a   Siedlak, Sandra ^a   Doughman, Yong Qiu ^a   Watanabe, Michiko ^a   Montano, Monica M ^a  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Aromatase; Hyperplasia; Oxidative DNA damage

Indexed keywords

AROMATASE; DIARYLPROPIONITRILE; DOXYCYCLINE; ESTROGEN; ESTROGEN RECEPTOR BETA; PLACEBO; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE); TAMOXIFEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; ATYPICAL DUCTAL HYPERPLASIA; BREAST CARCINOGENESIS; CELL PROLIFERATION; CONTROLLED STUDY; DNA DAMAGE; ENZYME INDUCTION; MAMMARY GLAND; MOUSE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; TRANSGENIC MOUSE;

ANIMALS; AROMATASE; BLOTTING, WESTERN; ESTROGEN ANTAGONISTS; ESTROGEN RECEPTOR BETA; IMMUNOHISTOCHEMISTRY; IN SITU NICK-END LABELING; MAMMARY GLANDS, ANIMAL; MAMMARY NEOPLASMS, ANIMAL; MICE; MICE, TRANSGENIC; NAD(P)H DEHYDROGENASE (QUINONE); NITRILES; TAMOXIFEN;

MUS; MUS MUSCULUS;

EID: 84868089323     PISSN: None     EISSN: 15306860     Source Type: Journal    
DOI: 10.1096/fj.12-208330     Document Type: Article

References (48)

1. Liehr, J. G. (2000) Is estradiol a genotoxic mutagenic carcinogen? Endocr. Rev. 21, 40-54
2. Yager, J. D., and Davidson, N. E. (2006) Estrogen carcinogenesis in breast cancer. N. Engl. J. Med. 354, 270-282
3. Simpson, E. R., Mahendroo, M. S., Means, G. D., Kilgore, M. W., Hinshelwood, M. M., Graham-Lorence, S., Amarneh, B., Ito, Y., Fisher, C. R., Michael, M. D., Mendelson, C. R., and Bulun, S. E. (1994) Aromatase cytochrome P450, the enzyme responsible for estrogen biosynthesis. Endocr. Rev. 15, 342-355
4. Agarwal, V. R., Bulun, S. E., Leitch, M., Rohrich, R., and Simpson, E. R. (1996) Use of alternative promoters to express the aromatase cytochrome P450 (CYP19) gene in breast adipose tissues of cancer-free and breast cancer patients. J. Clin. Endocrinol. Metab. 81, 3843-3849
5. Miller, W. R., Mullen, P., Sourdaine, P., Watson, C., Dixon, J. M., and Telford, J. (1997) Regulation of aromatase activity within the breast. J. Steroid Biochem. Mol. Biol. 61, 193-202
6. Tekmal, R. R., Ramachandra, N., Gubba, S., Durgam, V. R., Mantione, J., Toda, K., Shizuta, Y., and Dillehay, D. L. (1996) Overexpression of int-5/aromatase in mammary glands of transgenic mice results in the induction of hyperplasia and nuclear abnormalities. Cancer Res. 56, 3180-3185
7. Kirma, N., Gill, K., Mandava, U., and Tekmal, R. R. (2001) Overexpression of aromatase leads to hyperplasia and changes in the expression of genes involved in apoptosis, cell cycle, growth, and tumor suppressor functions in the mammary glands of transgenic mice. Cancer Res. 61, 1910-1918
8. Santen, R. J., Brodie, H., Simpson, E. R., Siiteri, P. K., and Brodie, A. (2009) History of aromatase: saga of an important biological mediator and therapeutic target. Endocr. Rev. 30, 343-375
9. Smith, I. E., and Dowsett, M. (2003) Aromatase inhibitors in breast cancer. N. Engl. J. Med. 348, 2431-2442
10. Cuzick, J., Forbes, J. F., Sestak, I., Cawthorn, S., Hamed, H., Holli, K., and Howell, A. (2007) Long-term results of tamoxifen prophylaxis for breast cancer-96-month follow-up of the randomized IBIS-I trial. J. Natl. Cancer Inst. 99, 272-282
11. Fisher, B., Costantino, J. P., Wickerham, D. L., Redmond, C. K., Kavanah, M., Cronin, W. M., Vogel, V., Robidoux, A., Dimitrov, N., Atkins, J., Daly, M., Wieand, S., Tan-Chiu, E., Ford, L., and Wolmark, N. (1998) Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J. Natl. Cancer Inst. 90, 1371-1388
12. Harris, H. A. (2007) Estrogen receptor-beta: recent lessons from in vivo studies. Mol. Endocrinol. 21, 1-13
13. Hopp, T. A., Weiss, H. L., Parra, I. S., Cui, Y., Osborne, C. K., and Fuqua, S. A. (2004) Low levels of estrogen receptor beta protein predict resistance to tamoxifen therapy in breast cancer. Clin. Cancer Res. 10, 7490-7499
14. Palmieri, C., Cheng, G. J., Saji, S., Zelada-Hedman, M., Warri, A., Weihua, Z., Van Noorden, S., Wahlstrom, T., Coombes, R. C., Warner, M., and Gustafsson, J. A. (2002) Estrogen receptor beta in breast cancer. Endocr. Relat. Cancer 9, 1-13
15. Saji, S., Hirose, M., and Toi, M. (2005) Clinical significance of estrogen receptor beta in breast cancer. Cancer Chemother. Pharmacol. 56(Suppl. 1), 21-26
16. Lazennec, G., Bresson, D., Lucas, A., Chauveau, C., and Vignon, F. (2001) ER beta inhibits proliferation and invasion of breast cancer cells. Endocrinology 142, 4120-4130
17. Omoto, Y., Eguchi, H., Yamamoto-Yamaguchi, Y., and Hayashi, S. (2003) Estrogen receptor (ER) beta1 and ERβcx/β2 inhibit ERα function differently in breast cancer cell line MCF7. Oncogene 22, 5011-5020
18. Paruthiyil, S., Parmar, H., Kerekatte, V., Cunha, G. R., Firestone, G. L., and Leitman, D. C. (2004) Estrogen receptor beta inhibits human breast cancer cell proliferation and tumor formation by causing a G2 cell cycle arrest. Cancer Res. 64, 423-428
19. Meyers, M. J., Sun, J., Carlson, K. E., Marriner, G. A., Katzenellenbogen, B. S., and Katzenellenbogen, J. A. (2001) Estrogen receptor-beta potency-selective ligands: structure-activity relationship studies of diarylpropionitriles and their acetylene and polar analogues. J. Med. Chem. 44, 4230-4251
20. Helguero, L. A., Faulds, M. H., Gustafsson, J. A., and Haldosen, L. A. (2005) Estrogen receptors alfa (ERα) and beta (ERβ) differentially regulate proliferation and apoptosis of the normal murine mammary epithelial cell line HC11. Oncogene 24, 6605-6616
21. Hodges-Gallagher, L., Valentine, C. D., El Bader, S., and Kushner, P. J. (2008) Estrogen receptor beta increases the efficacy of antiestrogens by effects on apoptosis and cell cycling in breast cancer cells. Breast Cancer Res. Treat. 109, 241-250
22. Montano, M. M., Jaiswal, A. K., and Katzenellenbogen, B. S. (1998) Transcriptional regulation of the human quinone reductase gene by antiestrogen-liganded estrogen receptor-α and estrogen receptor-β. J. Biol. Chem. 273, 25443-25449
23. Bianco, N. R., Perry, G., Smith, M. A., Templeton, D. J., and Montano, M. M. (2003) Functional implications of antiestrogen induction of quinone reductase: inhibition of estrogen-induced deoxyribonucleic acid damage. Mol. Endocrinol. 17, 1344-1355
24. Montano, M. M., Chaplin, L. J., Deng, H., Mesia-Vela, S., Gaikwad, N., Zahid, M., and Rogan, E. (2007) Protective roles of quinone reductase and tamoxifen against estrogen-induced mammary tumorigenesis. Oncogene 26, 3587-3590
25. Bianco, N. R., Chaplin, L. J., and Montano, M. M. (2005) Differential induction of quinone reductase by phytoestrogens and protection against oestrogen-induced DNA damage. Biochem. J. 385, 279-287
26. Sripathy, S. P., Chaplin, L. J., Gaikwad, N. W., Rogan, E. G., and Montano, M. M. (2008) hPMC2 is required for recruiting an ERβ coactivator complex to mediate transcriptional upregulation of NQO1 and protection against oxidative DNA damage by tamoxifen. Oncogene 27, 6376-6384
27. Tekmal, R. R., Liu, Y. G., Nair, H. B., Jones, J., Perla, R. P., Lubahn, D. B., Korach, K. S., and Kirma, N. (2005) Estrogen receptor alpha is required for mammary development and the induction of mammary hyperplasia and epigenetic alterations in the aromatase transgenic mice. J. Steroid Biochem. Mol. Biol. 95, 9-15
28. O'Regan, R. M., Cisneros, A., England, G. M., MacGregor, J. I., Muenzner, H. D., Assikis, V. J., Bilimoria, M. M., Piette, M., Dragan, Y. P., Pitot, H. C., Chatterton, R., and Jordan, V. C. (1998) Effects of the antiestrogens tamoxifen, toremifene, and ICI 182,780 on endometrial cancer growth. J. Natl. Cancer Inst. 90, 1552-1558
29. Schafer, J. M., Lee, E. S., O'Regan, R. M., Yao, K., and Jordan, V. C. (2000) Rapid development of tamoxifen-stimulated mutant p53 breast tumors (T47D) in athymic mice. Clin. Cancer Res. 6, 4373-4380
30. Frasor, J., Barnett, D. H., Danes, J. M., Hess, R., Parlow, A. F., and Katzenellenbogen, B. S. (2003) Response-specific and ligand dose-dependent modulation of estrogen receptor (ER) α activity by ERβ in the uterus. Endocrinology 144, 3159-3166
31. Dong, L., Wang, W., Wang, F., Stoner, M., Reed, J. C., Harigai, M., Samudio, I., Kladde, M. P., Vyhlidal, C., and Safe, S. (1999) Mechanisms of transcriptional activation of bcl-2 gene expression by 17β-estradiol in breast cancer cells. J. Biol. Chem. 274, 32099-32107
32. Nair, H. B., Kirma, N. B., Ganapathy, M., Vadlamudi, R. K., and Tekmal, R. R. (2011) Estrogen receptor-beta activation in combination with letrozole blocks the growth of breast cancer tumors resistant to letrozole therapy. Steroids 76, 792-796
33. Lu, B., Leygue, E., Dotzlaw, H., Murphy, L. J., and Murphy, L. C. (2000) Functional characteristics of a novel murine estrogen receptor-beta isoform, estrogen receptor-beta 2. J. Mol. Endocrinol. 25, 229-242
34. Tremblay, G. B., Tremblay, A., Copeland, N. G., Gilbert, D. J., Jenkins, N. A., Labrie, F., and Giguere, V. (1997) Cloning, chromosomal localization, and functional analysis of the murine estrogen receptor beta. Mol. Endocrinol. 11, 353-365
35. Mandava, U., Kirma, N., and Tekmal, R. R. (2001) Aromatase overexpression transgenic mice model: cell type specific expression and use of letrozole to abrogate mammary hyperplasia without affecting normal physiology. J. Steroid Biochem. Mol. Biol. 79, 27-34
36. Tekmal, R. R., Kirma, N., Gill, K., and Fowler, K. (1999) Aromatase overexpression and breast hyperplasia, an in vivo model-continued overexpression of aromatase is sufficient to maintain hyperplasia without circulating estrogens, and aromatase inhibitors abrogate these preneoplastic changes in mammary glands. Endocr. Relat. Cancer 6, 307-314
37. Asher, G., Lotem, J., Cohen, B., Sachs, L., and Shaul, Y. (2001) Regulation of p53 stability and p53-dependent apoptosis by NADH quinone oxidoreductase 1. Proc. Natl. Acad. Sci. U. S. A. 98, 1188-1193
38. Sollner, S., Durchschlag, M., Frohlich, K. U., and Macheroux, P. (2009) The redox-sensing quinone reductase Lot6p acts as an inducer of yeast apoptosis. FEMS Yeast Res. 9, 885-891
39. Iskander, K., Gaikwad, A., Paquet, M., Long, D. J., 2nd, Brayton, C., Barrios, R., and Jaiswal, A. K. (2005) Lower induction of p53 and decreased apoptosis in NQO1-null mice lead to increased sensitivity to chemical-induced skin carcinogenesis. Cancer Res. 65, 2054-2058
40. Iskander, K., and Jaiswal, A. K. (2005) Quinone oxidoreductases in protection against myelogenous hyperplasia and benzene toxicity. Chem. Biol. Interact. 153-154, 147-157
41. Jaiyesimi, I. A., Buzdar, A. U., Decker, D. A., and Hortobagyi, G. N. (1995) Use of tamoxifen for breast cancer: twenty-eight years later. J. Clin. Oncol. 13, 513-529
42. Shou, J., Massarweh, S., Osborne, C. K., Wakeling, A. E., Ali, S., Weiss, H., and Schiff, R. (2004) Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer. J. Natl. Cancer Inst. 96, 926-935
43. Cushman, M., Costantino, J. P., Bovill, E. G., Wickerham, D. L., Buckley, L., Roberts, J. D., and Krag, D. N. (2003) Effect of tamoxifen on venous thrombosis risk factors in women without cancer: the Breast Cancer Prevention Trial. Br. J. Haematol. 120, 109-116
44. Day, R., Ganz, P. A., Costantino, J. P., Cronin, W. M., Wickerham, D. L., and Fisher, B. (1999) Health-related quality of life and tamoxifen in breast cancer prevention: a report from the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J. Clin. Oncol. 17, 2659-2669
45. Coombes, R. C., Kilburn, L. S., Snowdon, C. F., Paridaens, R., Coleman, R. E., Jones, S. E., Jassem, J., Van de Velde, C. J., Delozier, T., Alvarez, I., Del Mastro, L., Ortmann, O., Diedrich, K., Coates, A. S., Bajetta, E., Holmberg, S. B., Dodwell, D., Mickiewicz, E., Andersen, J., Lonning, P. E., Cocconi, G., Forbes, J., Castiglione, M., Stuart, N., Stewart, A., Fallowfield, L. J., Bertelli, G., Hall, E., Bogle, R. G., Carpentieri, M., Colajori, E., Subar, M., Ireland, E., and Bliss, J. M. (2007) Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. Lancet 369, 559-570
46. Forbes, J. F., Cuzick, J., Buzdar, A., Howell, A., Tobias, J. S., and Baum, M. (2008) Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol. 9, 45-53
47. Walf, A. A., Koonce, C. J., and Frye, C. A. (2008) Estradiol or diarylpropionitrile decrease anxiety-like behavior of wildtype, but not estrogen receptor beta knockout, mice. Behav. Neurosci. 122, 974-981
48. Weiser, M. J., Wu, T. J., and Handa, R. J. (2009) Estrogen receptor-β agonist diarylpropionitrile: biological activities of Rand S-enantiomers on behavior and hormonal response to stress. Endocrinology 150, 1817-1825